Literature DB >> 23006672

Effect of anticoagulation regimens on handling of interleukin-6 and -8 during continuous venovenous hemofiltration in critically ill patients with acute kidney injury.

Louise Schilder1, S Azam Nurmohamed, Pieter M ter Wee, Armand R J Girbes, Albertus Beishuizen, Nanne J Paauw, Robert H J Beelen, A B Johan Groeneveld.   

Abstract

OBJECTIVE: During continuous venovenous hemofiltration (CVVH) to replace renal function in acute kidney injury (AKI), anticoagulation of the filter is routinely required. A survival benefit for citrate has been reported, possibly due to reduced proinflammatory effects of the filter (bioincompatibility). We hypothesized that the type of anticoagulation modulates the immune response to, and clearance by CVVH of interleukin-6 (IL-6) and -8 (IL-8).
METHODS: Three anticoagulation regimens were compared: trisodium citrate (n=17), unfractionated heparin (n=8) and no anticoagulation in case of bleeding tendency (n=13). Immediately before initiation of CVVH (cellulose triacetate membrane) pre-filter blood was drawn. Thereafter, at 10, 60, 180 and 720 min, samples were collected from the pre- and postfilter blood and from ultrafiltrate. IL-6 and IL-8 were determined by ELISA.
RESULTS: High inlet levels of IL-6 and IL-8, particularly in the no anticoagulation group, were associated with non-survival. The inlet concentrations and mass rates of IL-6 and IL-8 decreased during CVVH. The course of fluxes across the filter were similar for the groups, however. Although increasing in time for IL-6 in the no anticoagulation group, mass removal and adsorption of IL-6 and IL-8 were low and did not differ among the anticoagulation groups.
CONCLUSIONS: Blood to membrane contact, adsorption/clearance and anticoagulation do not increase nor attenuate high circulating levels of IL-6 and IL-8 during CVVH for AKI. This renders the hypothesis that the reported survival benefit for citrate anticoagulation is based on a reduction of bioincompatibility unlikely.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23006672     DOI: 10.1016/j.cyto.2012.08.015

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

1.  Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities.

Authors:  Louise Schilder; S Azam Nurmohamed; Pieter M ter Wee; Nanne J Paauw; Armand R J Girbes; Albertus Beishuizen; Robert H J Beelen; A B Johan Groeneveld
Journal:  BMC Nephrol       Date:  2015-10-30       Impact factor: 2.388

2.  The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied.

Authors:  Louise Schilder; S Azam Nurmohamed; Pieter M ter Wee; Nanne J Paauw; Armand R J Girbes; Albertus Beishuizen; Robert H J Beelen; A B Johan Groeneveld
Journal:  Crit Care       Date:  2014-04-22       Impact factor: 9.097

3.  Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure--a prospective, randomised crossover study.

Authors:  Christoph Sponholz; Katja Matthes; Dina Rupp; Wolf Backaus; Sebastian Klammt; Diana Karailieva; Astrid Bauschke; Utz Settmacher; Matthias Kohl; Mark G Clemens; Steffen Mitzner; Michael Bauer; Andreas Kortgen
Journal:  Crit Care       Date:  2016-01-04       Impact factor: 9.097

4.  Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients.

Authors:  Louise Schilder; S Azam Nurmohamed; Pieter M ter Wee; Nanne J Paauw; Armand R J Girbes; Albertus Beishuizen; Robert H J Beelen; A B Johan Groeneveld
Journal:  BMC Nephrol       Date:  2014-01-17       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.